Compare ECCC & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECCC | INM |
|---|---|---|
| Founded | N/A | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 3.7M |
| IPO Year | N/A | N/A |
| Metric | ECCC | INM |
|---|---|---|
| Price | $24.80 | $1.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 137.3K |
| Earning Date | N/A | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,798,116.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $1.13 |
| 52 Week High | N/A | $8.27 |
| Indicator | ECCC | INM |
|---|---|---|
| Relative Strength Index (RSI) | 66.92 | 40.93 |
| Support Level | $24.62 | $1.18 |
| Resistance Level | $24.90 | $1.35 |
| Average True Range (ATR) | 0.27 | 0.10 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 76.74 | 17.19 |
Eagle Point Credit Co Inc. is an externally managed, non-diversified closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective of capital appreciation. The Company seeks to achieve its investment objectives by investing in equity and junior debt tranches of collateralized loan obligations ("CLOs") collateralized by a portfolio consisting of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors. The Company intends to operate so as to qualify to be taxed as a regulated investment company.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.